Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy
| Autor: | Houyun Teng, Peng Jin, Qiaohong Geng, Jinlong Dong, Peifu Jiao, Bing Yan, Gaoxing Su |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_treatment
Programmed Cell Death 1 Receptor Small Molecule Libraries 03 medical and health sciences 0302 clinical medicine Immune system Cancer immunotherapy Neoplasms PD-L1 Drug Discovery medicine Humans 030304 developmental biology Pharmacology 0303 health sciences biology business.industry Immunogenicity Cancer medicine.disease Small molecule Blockade 030220 oncology & carcinogenesis biology.protein Cancer research Immunotherapy Antibody business |
| Zdroj: | Current Pharmaceutical Design. 24:4911-4920 |
| ISSN: | 1381-6128 |
| DOI: | 10.2174/1381612824666181112114958 |
| Popis: | Blockade of PD-1/PD-L1 interactions using PD-1/PD-L1 pathway modulators has shown unprecedented clinical efficacy in various cancer models. Current PD-1/PD-L1 modulators approved by FDA are exclusively dominated by therapeutic antibodies. Nevertheless, therapeutic antibodies also exhibit several disadvantages such as low tumor penetration, difficulty in crossing physiological barriers, lacking oral bioavailability, high manufacturing costs, inaccessible to intracellular targets, immunogenicity, immune-related adverse events (irAEs). Modulation of PD-1/PD-L1 pathway using small molecules may be an alternative approach to mobilize immune system to fight against cancers. In this review, we focus on summarizing the recently disclosed chemical structures and preliminary structure-activity relationships (SARs) of small molecules as PD-1/PD-L1 modulators for cancer immunotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|